ym 872 has been researched along with Cranial Nerve II Injuries in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, CA; Fitzgerald, M; Gavriel, N; Gopalasingam, G; Majimbi, M; McGonigle, T; Rodger, J; Toomey, LM | 1 |
| Bartlett, CA; Chiha, W; Fitzgerald, M; Giacci, MK; Harvey, AR; Hodgetts, SI; O'Hare Doig, RL; Smith, NM; Yates, NJ | 1 |
| Bartlett, CA; Fitzgerald, M; Gopalasingam, G; Majimbi, M; Rodger, J; Toomey, LM | 1 |
3 other study(ies) available for ym 872 and Cranial Nerve II Injuries
| Article | Year |
|---|---|
Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Drug Therapy, Combination; Female; Imidazoles; Myelin Sheath; Nerve Degeneration; Optic Nerve; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptors, AMPA; Receptors, Purinergic P2X7; Rosaniline Dyes | 2019 |
Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal; Female; Imidazoles; Macrophages; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Optic Nerve Injuries; Oxidative Stress; Piperazines; Purinergic P2X Receptor Antagonists; Quinoxalines; Random Allocation; Ranvier's Nodes; Rats; Receptors, AMPA; Receptors, Purinergic P2X7 | 2017 |
Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Ectodysplasins; Female; Imidazoles; Ion Channels; Macrophages; Microfilament Proteins; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Oligodendrocyte Transcription Factor 2; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Rosaniline Dyes; Tubulin | 2019 |